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It is well known that interferon-y (IFN-)I; type II) potentiates various responses of human tumor necrosis factor (TNF) in a wide variety of cells 
and that this potentiation is accompanied by the up-regulation of TNF receptor synthesis. In the present studies we examined the regulation of TNF 
receptors by type I and type II IFNs in a hepatocellular carcinoma cell line, HEP G2. Exposure of these cells to IFN-y led to a decrease in TNF 
receptor number (4029 vs. 2719 sites/cell) without any change in the receptor aftinity (0.96 nM vs. 1.1 nM). The effect was time and dose-dependent. 
Like IFN-y, IFN-a and IF%B (type I) down-modulated the TNF receptors on these cells. The effect of IFNs on the TNF receptors was inhibited 
by staurosporin, a protein kinase C (PK-C) inhibitor. Furthermore, by the use of receptor-specific antibodies, we found that the IFN-dependent 
decrease was primarily due to the p60 form of the TNF receptor. Our results presented are the first to demonstrate that IFNs can also down-modulate 
TNF receptors in certain cells and that this effect is mediated through PK-C. 
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1. Introduction 
Soon after human tumor necrosis factor (TNF) was 
isolated to homogeneity, it was found to synergize with 
interferon-y (IFN-y) in inducing antiproliferative ffects 
against a wide variety of tumor cells [l-5]. Very quickly, 
demonstration of this synergistic action was extended to 
several other effects of TNF [l]. Our laboratory and 
several others have reported that IFN-y increases TNF 
receptor numbers on a wide variety of cells, which per- 
haps accounts for the synergistic effects in at least some 
systems [6-l 11. 
We have recently reported that IFNs, both type I 
(IFN-cx and IFN-/3) and type II (IFN-)I), upregulate both 
p60 and p80 forms of the TNF receptors in a wide variety 
of cells [12]. In the present report, we demonstrate that 
in Hep G2 cells the IFNs down-modulate TNF receptors 
and that this effect is mediated through the activation of 
a protein kinase-C. Further, we show that it is the p60 
receptor that is down-modulated. 
*Corresponding author. Fax: (1) (713) 794 1613. 
Abbreviations: TNF, tumor necrosis factor; IFN, interferon; ~60, also 
referred to as ~55, TNF receptor I, or TNF receptor type B; ~80, also 
referred to as ~75, TNF receptor II, or TNF receptor type A; FCS, fetal 
calf serum; PK-C, protein kinase C. 
2. Materials and methods 
2.1. Materials 
Bacteria-derived recombinant human TNF-a, IFN-a, and IFN-y 
purified to homogeneity with a specific activity of 50 x 106, 100 x lo6 
and 10 x lo6 units/mg, respectively, were kindly provided by Genen- 
tech, Inc., South San Francisco, CA. Recombinant human IFN-/3 with 
a specific activity of 10 x lo6 units/mg protein was a kind gift of Toray 
Ltd., Tokyo, Japan. Polyclonal antibodies against each type of soluble 
receptor were raised in rabbits and purified by receptor-aflinity chrom- 
atography. 
2.2. Cell lines 
The human hepatocellular carcinoma cell line HepG2 (ATCC No. 
HB-8065) was grown in DMEM supplemented with fetal calf serum 
(FCS) (10%) and gentamicin (50 &ml). The cells were seeded at a 
density of 1 x lo5 cells/ml in T-25 flasks (Falcon 3013, Becton Dickin- 
son Labware, Lincoln Park, NJ) containing 10 ml of medium and 
grown at 37°C in an atmosphere of 95% air and 5% CO,. Cell cultures 
were split every 3 or 4 days. 
2.3. Receptor-binding assay 
Recombinant human TNF was labeled with Nalz51 using the Iodogen 
procedure as described previously [6]. The specific activity of labeled 
TNF was 30 @/pg. Binding assays were performed in 12-well plates 
as described [6]. Briefly, cells (0.2 x lo6 cells/well) were incubated in 
binding buffer (DMEM supplemented with 10% FCS) with ‘Z51-labeled 
TNF (0.2 x lo6 cpm) with or without 250 nM TNF in a total final 
volume of 0.5 ml for 1 h at 4°C. Thereafter, cells were washed three 
times with 0.5 ml of ice-cold washing buffer (PBS containing 0.1% 
BSA). Cell-bound radioactivity was then determined by a Packard 
gamma counter (model CD 5010). 
The binding of TNF to p60 or p80 receptor was determined by 
preincubating the cells at 37°C for 1 h with 0.6-0.8 &ml of either 
preimmune or anti-p60 or anti-p80 antibodies before initiating the 
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ligand binding. The amount of p60 or ~80 receptor was calculated by 
subtracting TNF-specific binding in the absence of antibody from that 
in the presence of either anti-p80 or anti-p60 receptor antibodies. All 
determinations were made in triplicate and expressed as mean f SE. 
3. Results 
3.1. Interferon-y down-modulates TNF receptors 
We first examined the effect of pretreatment of IFN-y 
on TNF receptors in Hep G2 cells. For this, cells were 
treated with different concentrations of IFN-y for 18 h 
at 37”C, washed, and examined for TNF receptors. The 
results shown in Fig. la demonstrate that IFN-y pro- 
duces a dose-dependent decrease in TNF receptors. A 
maximum decrease was observed at 100 ng/ml of IFN. 
The decrease in TNF receptors by IFN-y under these 
conditions was not due to its effect on cell viability as 
determined by Trypan blue exclusion and also by triti- 
ated thymidine incorporation (data not shown). We also 
examined the time-course of down-modulation of TNF 
receptors by 100 &ml of IFN. The results of this exper- 
iment (Fig. lb) indicate that receptor decreased in a time- 
dependent manner reaching maximum levels at 18 h. To 
determine whether the decrease in binding of TNF to the 
cells was due to receptor number or receptor affinity, we 
carried out competitive TNF receptor binding and per- 
formed Scatchard analysis. The results of these experi- 
ments (Fig. 2a,b) demonstrate that TNF receptor num- 
ber decreased but receptor affinity did not. 
3.2. TNF receptors are also down-modulated by IFN-a 
and IFN_B 
Since the biological responses of IFN-a and IFN-p are 
mediated through a receptor distinct from that of IFN-y 
[13], we examined the effect of the type I IFNs on the 
TNF receptors in HepG2 cells. As shown in Table 1, all 
three IFNs down-modulated the binding of TNF to these 
cells. The effect appeared to be very comparable, al- 
though IFN-a seemed somewhat less effective than the 
other IFNs. 
3.3. Staurosporin inhibits down-modulation of IFN- 
induced TNF receptors 
Staurosporin is a well-known inhibitor of protein ki- 
nase C (PK-C) [14]. Since it has been reported that some 
of the effects of IFNs are PK-C mediated [15-171, we 
examined the effect of staurosporin on the interferon- 
induced down-modulation of TNF receptors. The results 
of this experiment, shown in Table 1, demonstrate that 
though the PK-C inhibitor had no effect by itself on TNF 
receptors, it completely abolished the down-modulation 
of the receptor by IFN-y. Staurosporin was also effective 
against IFN-a and IFN-B but not to the same extent as 
against IFN-y. These results suggest that the down-mod- 
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Fig. 1. Dose-dependency (upper panel) and time course (lower panel) 
of down-modulation of TNF receptor by IFN-r. Cells (2 x 105) were 
incubated with different concentrations of IFN-y for 18 h at 37°C 
(upper panel) or with 100 ng/ml IFN-r for different times at 37OC 
(lower panel), washed, and tested for TNF receptors as described in 
Section 2. 
ulation of TNF receptors by IFNs may be PK-C-medi- 
ated. 
3.4. The p60 form of the TNF receptor is modulated by 
IFN 
We examined which of the TNF receptors, referred to 
as type I or p60 and type II or p80 was modulated by 
IFN-y. We used antibodies specific to each receptor to 
block ligand binding. The results in Table 2 indicate that 
HepG2 cells essentially expressed only the p60 form of 
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Fig. 2. Competitive TNF receptor binding analysis (upper panel) and 
Scatchard analysis (lower panel) of TNF binding to untreated HepG2 
cells and HepG2 cells treated with IFN-y. Cells (2 x 105) were incubated 
with 100 ng/ml IFN-y for 18 h at 37OC, washed, and tested for TNF 
receptors as described in Section 2. 
the TNF receptor, and it is this receptor that was down- 
modulated by IFN-y. 
4. Dlacussion 
Several previous reports have indicated that TNF re- 
ceptors are up-regulated by treatment of cells with IFN- 
y [6-l 11. In the present report, however, we demonstrate 
that treatment of Hep G2 cells with IFN-)I down-modu- 
lates the TNF receptors. Similar to IFN-7, IFN-a and 
IFN-p also caused a decrease in the receptors. IFNs 
induced a decrease in TNF receptor number without any 
effect on the affinity. 
Table 1 
Effect of staurosporine on interferons-induced TNF-receptor down- 
regulation in HepG2 cells 
Treatment Specific binding (cpm) 
Control Staurosporin 
treatment 
None 929 f 80 957 f 63 
IFN-y 651 f 90 948 f 55 
IFN-a 742 +- 14 803 +_ 69 
IFN-j’I 640 f 50 711 f 95 
0.2 x lo6 cells were incubated overnight with each interferon (100 ng/ 
ml) and without or with staurosporine (3 nM) at 37’C for 18 h and then 
washed off and examined for TNF receptors as indicated in Section 2. 
All determinations were made in truplicate. 
How IFNs mediate a decrease in TNF receptors is not 
clear. Since the down-modulation of TNF receptors by 
IFNs could be prevented by staurosporin, a PK-C inhib- 
itor, IFNs may activate a PK-C that in turn decreases the 
number of TNF receptors. IFN-a and IFN-/? bind to a 
common receptor that is distinct from that of IFN-y [ 131. 
Even though both IFN receptors lack intrinsic protein 
kinase activity, they do, however, activate PK-C which 
has been shown to be critical for the transcriptional ac- 
tivity of the IFNs [15-l 71. A novel staurosporin-sensitive 
kinase has been shown to be required for the induction 
of a transcriptional factor ISGF3 needed for the signal 
transduction of IFN-a [15]. Therefore, it is possible that 
the same staurosporin-sensitive kinase is involved in the 
downmodulation of TNF receptors. 
Our results on the downmodulation of TNF receptors 
through the PK-C pathway are consistent with previous 
reports indicating that treatment of cells with phorbol 
esters, which are activators of PK-C, and okadaic acid, 
an inhibitor of serine-threonine phosphatase, also down- 
modulate TNF receptors [ 18,191. 
Our results also indicate that among the two types of 
TNF receptors, the p60 form is primarily expressed by 
HepG2, and it is this receptor that is down-modulated 
Table 2 
Down-modulation of tumor necrosis factor receptors by IFN-y on 
HepG2 cells 
Antibody Specific TNF binding (cpm) 
Control IFN-y 
None 613 f 1 442+7 
Preimmune 522 f 120 433 + 6 
~60 93 f 6 60 f 3 
~80 359 + 34 447f80 
0.2 x lo6 cells were incubated with IFN-y (100 @ml) overnight and 
then washed. Cells were then preincubated with either pre-immune or 
anti-p60 or anti-p80 for 1 h at 37’C and then examined for remaining 
TNF receptors. 
102 B.B. Aggarwal, R PanditalFEBS Letters 337 (1994) 99-102 
by IFNs. In contrast to the ~80 receptor, the p60 form 
of the TNF receptor has been implicated in a wide vari- 
ety of biological effects [20]. Therefore, it is possible that 
the modulation of the p60 receptor by IFNs has a direct 
effect on the biological response to TNF. 
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